Taysha reports mixed earnings as gene therapy trials advance
Revenue beats expectations but EPS misses; $319.8M cash runway funds Rett syndrome program through 2028
Taysha Gene Therapies reported full-year 2025 financial results on Thursday, delivering a significant revenue surprise while missing earnings expectations, as the gene therapy company advances its lead program targeting Rett syndrome.
The Dallas-based biotechnology company reported revenue of $9.8 million, substantially exceeding analyst forecasts that had projected approximately $6.5 million for the full year. However, the company recorded an earnings per share loss of $0.34, worse than the expected loss of $0.09 per share.
For clinical-stage biotechnology companies, however, earnings typically take a backseat to clinical trial progress and cash runway. Taysha's stock closed at $4.45 on Thursday, down 2.6 percent, giving the company a market capitalization of approximately $1.25 billion.
The company's balance sheet remains robust, with $319.8 million in cash and cash equivalents as of December 31, 2025. Management indicated this capital position will fund planned operating expenses into 2028, providing substantial runway to advance its lead candidate through late-stage trials.
Taysha's flagship program, TSHA-102, is an adeno-associated virus-based gene therapy targeting Rett syndrome, a rare neurodevelopmental disorder that primarily affects girls. The company reported significant progress across its clinical pipeline, including the pivotal REVEAL trial where multiple patients have been dosed and enrollment is advancing across multiple sites. Management expects to complete dosing for all participants in the second quarter of 2026.
Critically, TSHA-102 has demonstrated a favorable safety profile with no treatment-related serious adverse events or dose-limiting toxicities reported across the REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026. In earlier trials, the therapy demonstrated a 100 percent response rate, with patients gaining or regaining one or more defined developmental milestones.
"TSHA-102 continues to be generally well-tolerated," the company stated in its earnings release, highlighting the absence of safety concerns that have plagued some gene therapy candidates in development.
Taysha has also secured regulatory clarity for its submission strategy. The company has achieved written alignment with the FDA on the proposed Process Performance Qualification and comparability strategy for commercial TSHA-102 manufacturing, which will support the planned Biologics License Application submission. The ASPIRE trial, targeting patients aged 2 to less than 4 years, has received FDA clearance with dosing expected to complete in the second quarter of 2026.
The Rett syndrome treatment market represents a significant commercial opportunity. Currently valued at approximately $182.6 million, the market is projected to grow to between $419.4 million and $634.5 million by the early 2030s, driven by increasing diagnosis rates and the introduction of novel therapies.
TSHA-102 has received multiple expedited regulatory designations from the FDA, including Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. These designations are designed to accelerate the development and review of drugs for serious conditions.
The competitive landscape for Rett syndrome remains relatively sparse. Acadia Pharmaceuticals' DAYBUE (trofinetide), approved in March 2023 for symptom management, is currently the only FDA-approved treatment for the disorder. Neurogene's NGN-401 represents another gene therapy candidate currently in Phase I/II trials, but TSHA-102 is positioned as a leading contender in the gene therapy approach.
Wall Street maintains a bullish outlook on Taysha, with analysts uniformly rating the stock a Buy or Strong Buy. The consensus price target stands at $11.00, with a range from $7.00 to $19.00, implying approximately 140 percent upside from current levels. Of the 14 analysts covering the stock, 11 rate it a Buy and 3 rate it a Strong Buy, with no Hold, Sell, or Strong Sell ratings.
Operating expenses for the full year 2025 totaled $120.3 million, comprising $86.4 million in research and development spending and $33.9 million in general and administrative expenses. The company reported a net loss of $109.0 million for the year.
Looking ahead, investors will focus on interim data readouts from the REVEAL pivotal trial expected in the second quarter of 2026, as well as the completion of dosing across both the REVEAL and ASPIRE trials. Successful results would position TSHA-102 as a potential first-in-class gene therapy for a devastating neurological disorder with limited treatment options.
The company's substantial cash position and clear regulatory pathway provide multiple de-risked catalysts through the remainder of 2026, even as the earnings miss highlights the ongoing capital requirements of advancing gene therapy candidates through late-stage clinical development.